Abstract
Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve®) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use device that uses the Staccato® drug delivery system. With Adasuve®, maximum plasma loxapine concentrations are reached in a median of 2 min. In two randomized, double-blind, placebo-controlled, multicentre trials, inhaled loxapine 5 or 10 mg significantly reduced agitation (assessed using Positive and Negative Syndrome Scale-Excited Component scores) in patients with bipolar I disorder or schizophrenia, with the onset of effect seen within 10 min of administration. Inhaled loxapine was generally well tolerated in phase III trials (which excluded patients with clinically significant acute or chronic pulmonary disease), with the most commonly occurring adverse events including dysgeusia and sedation. Inhaled loxapine is contraindicated in patients with airways disease associated with bronchospasm or acute respiratory signs or symptoms. In conclusion, inhaled loxapine provides a novel new option for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia, combining a rapid onset of effect with a noninvasive route of administration.
Similar content being viewed by others
References
Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(Suppl. 10):5–12.
Caine ED. Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatry. 2006;67(Suppl 10):22–31.
Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11(Suppl. 1):5–108.
Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry project BETA psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26–34.
Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med. 2006;47(1):79–99.
Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006;67(Suppl. 10):13–21.
Nordstrom K. Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: an update. Neuropsychiatry. 2012;2(3):253–60.
Chakrabarti A, Bagnall AM, Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007(4):CD001943.
Alexza Pharmaceuticals Inc. Adasuve™ (loxapine) inhalation powder, for oral inhalation use: US prescribing information; 2012. http://www.adasuve.com/ (Accessed 9 May 2013).
European Medicines Agency. Adasuve (loxapine) inhalation powder: EU summary of product characteristics; 2013. http://ec.europa.eu/health/documents/community-register/2013/20130220125343/anx_125343_en.pdf (Accessed 9 May 2013).
Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–8.
Cassella J, Spyker D, Kwentus J, et al. Rapid improvement in the five-item PANSS-EC scale for agitation with inhaled loxapine (AZ-004) [poster]. New Clinical Drug Evaluation Unit 2010 Meeting; 14–17 Jun 2010; Boca Raton (FL).
Alexza Pharmaceuticals. Adasuve (loxapine) inhalation powder NDA 022549: Psychopharmacologic Drug Advisory Committee briefing document. 2011. http://google2.fda.gov/search?q=cache:JPZyU1bYqqYJ:www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282900.pdf+Adasuve+(loxapine)+inhalation+powder+NDA+022549&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&access=p&oe=UTF-8 (Accessed 8 May 2013).
Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato® loxapine. Int J Pharm. 2011;403(1–2):101–8.
Gao Q, Lew A, Takahashi LH, et al. An investigation into the morphology of loxapine in a thermal aerosolization process from crystalline to amorphous. J Pharm Sci. 2011;100(4):1407–15.
Dinh KV, Myers DJ, Noymer PD, et al. In vitro aerosol deposition in the oropharyngeal region for Staccato® loxapine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):253–60.
Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2003;167(3):315–23.
Singh AN, Barlas C, Saeedi H, et al. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. J Psychiatry Neurosci. 2003;28(1):39–47.
Natesan S, VanderSpek S, Nobrega JN, et al. Contrasting loxapine to its isomer isoloxapine: the critical role of in vivo D2 blockade in determining atypicality. Schizophr Res. 2005;77(2–3):189–99.
Coupet J, Rauh CE. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol. 1979;55(2):215–8.
Singh AN, Barlas C, Singh S, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996;21(1):29–35.
Glazer WM. Does loxapine have ‘atypical’ properties? Clinical evidence. J Clin Psychiatry. 1999;60(Suppl. 10):42–6.
Meltzer HY, Matsubara S, Lee J-C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390–2.
Leysen JE, Janssen PMF, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl). 1993;112(1 Suppl.):S40–54.
Stockmeier CA, DiCarlo JJ, Zhang Y, et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther. 1993;266(3):1374–84.
Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154(11):1525–9.
Spyker DA, Gottwald MD, Fishman RS. The cardiovascular safety of inhaled loxapine (AZ-004) [abstract no. NR6-6 plus poster]. 163rd Annual Meeting of the American Psychiatric Association; 22–27 May 2010; New Orleans (LA).
US Food and Drug Administration. Clinical review: NDA 22549 SD-28; 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282897.pdf (Accessed 8 May 2013).
Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31–40.
Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169–79.
Luo JP, Vashishtha SC, Hawes EM, et al. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011;32(7):398–407.
Reed A, Huie K, Perloff ES, et al. Loxapine p-glycoprotein interactions in vitro. Drug Metab Lett. 2012;6(1):26–32.
Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313–21.
Cassella J, Fishman R. Treating agitation with inhaled loxapine (AZ-004): efficacy analyses in patients with schizophrenia or bipolar disorder [poster]. 24th Annual US Psychiatry and Mental Health Congress; 7–10 Nov 2011; Las Vegas (NV).
Howland RH. Now take a deep breath: inhaled loxapine for the treatment of acute agitation. J Psychosoc Nurs Ment Health Serv. 2012;50(1):16–8.
Otsuka Pharmaceutical Company. Abilify® (aripiprazole): US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021436s034,021713s025,021729s018,021866s020lbl.pdf (Accessed 9 May 2013).
Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(1):111–9.
Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149–51.
Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389–97.
European Medicines Agency. Abilify (aripiprazole): EU summary of product characteristics; 2013. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf (Accessed 9 May 2013).
Eli Lilly. Zyprexa (olanzapine): US prescribing information; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020592s057,021086s036,021253s045lbl.pdf (Accessed 9 May 2013).
European Medicines Agency. Zyprexa (olanzapine): EU summary of product characteristics; 2012. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000115/WC500055207.pdf (Accessed 9 May 2013).
Pfizer. Geodon (ziprasidone): US prescribing information; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020825s038,020919s025,021483s005lbl.pdf (Accessed 9 May 2013).
European Medicines Agency. Syncrest (asenapine) sublingual tablets: EU summary of product characteristics; 2013. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001177/WC500096895.pdf (Accessed 9 May 2013).
Merck and Co. Saphris® (asenapine) sublingual tablets: US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022117s013lbl.pdf (Accessed 9 May 2013).
Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract. 2011;65(3):330–40.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: P.G. Janicak, Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA; K. Nordstrom, Denver Health Medical Center, University of Colorado-Denver, Denver, CO, USA; S.L. Zeller, Department of Psychiatry, Alameda Health System, Oakland, CA, USA.
Rights and permissions
About this article
Cite this article
Keating, G.M. Loxapine Inhalation Powder: A Review of its Use in the Acute Treatment of Agitation in Patients with Bipolar Disorder or Schizophrenia. CNS Drugs 27, 479–489 (2013). https://doi.org/10.1007/s40263-013-0075-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-013-0075-9